CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
SJIF Impact Factor: 7.187
https://doi.org/10.5281/zenodo.18086858

Available online at: http://www.iajps.com Review Article

FORMULATION AND EVALUATION OF SOLID SELF MICROEMULSIFYING DRUG DELIVERY SYSTEM

Vaibhav Ankush Vhatkar[1*], Shashwat Pravin Kulkarni[2], Aditi Anil Patil[3], Omkar Hanmant Palkar[4], Shreya Pramod hillal[5], Prachiti Vasant Katkar[6], Chaitanya Santosh Kokate[7]

[1*, 2, 4, 7] Sahyadri College of Pharmacy Metavade, Sangola, Maharashtra - 413317
[3]Gandhi Natha Rangji College of D & B pharmacy, Solapur, Maharashtra - 413002
[5,6]SVERI's, college of Pharmacy, Pandharpur, Maharashtra 413304

Abstract:
Poor aqueous solubility remains one of the most significant challenges in the oral delivery of modern drug molecules, particularly those belonging to Biopharmaceutics Classification System (BCS) Class II and IV. Self-microemulsifying drug delivery systems (SMEDDS) have emerged as an effective lipid-based approach to enhance solubility, dissolution rate, and oral bioavailability of such drugs by forming fine oil-in-water microemulsions upon gastrointestinal dilution. However, conventional liquid SMEDDS suffer from several formulation and manufacturing limitations, including poor physical stability, leakage, capsule incompatibility, and limited dosage form flexibility. These drawbacks have led to the development of Solid Self-Microemulsifying Drug Delivery Systems (S-SMEDDS), which combine the biopharmaceutical advantages of liquid SMEDDS with the technological and patient-centric benefits of solid dosage forms.

This review comprehensively discusses the fundamental principles of SMEDDS, rationale for solidification, selection of excipients, and various preparation techniques employed for S-SMEDDS. Detailed characterization and evaluation strategies, including physicochemical, solid-state, in-vitro, and in-vivo assessments, are critically reviewed. The applications of S-SMEDDS in improving the oral delivery of antidiabetic, anticancer, antifungal, antiviral, central nervous system drugs, and herbal phytoconstituents are also highlighted. Overall, S-SMEDDS represent a promising and industrially viable platform for enhancing oral bioavailability and therapeutic performance of poorly water-soluble drugs.

Keywords:*Solid self-microemulsifying drug delivery systems; S-SMEDDS; Lipid-based drug delivery; Poorly water-soluble drugs; Oral bioavailability enhancement; BCS Class II and IV drugs; Solidification of SMEDDS.*

Corresponding author:
Vaibhav Ankush Vhatkar,
Sahyadri College of Pharmacy Metavade,
Sangola, Maharashtra – 413317
Email ID: vaibhavvhatkar2020@gmail.com

QR CODE

Please cite this article in press ***Vaibhav Ankush Vhatkar et al., Formulation And Evaluation Of Solid Self Microemulsifying Drug Delivery System,*** *Indo Am. J. P. Sci, 2025; 12(12).*

INTRODUCTION:

Challenges Associated with Poorly Water-Soluble Drugs (BCS Class II & IV)

A significant proportion of newly discovered and existing drug molecules belong to Biopharmaceutics Classification System (BCS) Class II and Class IV, which are characterized by low aqueous solubility, with Class IV drugs additionally exhibiting low intestinal permeability. Poor solubility is a critical limitation in oral drug delivery, as it directly affects the rate and extent of drug dissolution in gastrointestinal fluids, which is a prerequisite for absorption. Drugs with inadequate solubility often show erratic absorption, delayed onset of action, high inter- and intra-subject variability, and low oral bioavailability. To achieve therapeutic plasma concentrations, such drugs frequently require higher doses, which may lead to dose-dependent toxicity and adverse effects. Conventional approaches like salt formation, particle size reduction, and use of solubilizing agents often provide limited success, particularly for highly lipophilic molecules with complex chemical structures. These challenges necessitate advanced formulation strategies capable of maintaining drugs in a solubilized state throughout the gastrointestinal transit.

Need for Lipid-Based Drug Delivery Systems

Lipid-based drug delivery systems have emerged as an effective approach to overcome solubility-related limitations of poorly water-soluble drugs. These systems utilize oils, surfactants, and co-surfactants to dissolve lipophilic drugs and facilitate their transport in the gastrointestinal tract. Upon oral administration, lipid formulations can stimulate bile secretion and lipase activity, leading to the formation of mixed micelles that enhance drug solubilization and absorption. Additionally, lipid-based systems may promote lymphatic transport, thereby bypassing hepatic first-pass metabolism and improving systemic bioavailability. Compared to conventional solid dosage forms, lipid-based carriers provide improved dissolution behavior, reduced food effect, and more consistent pharmacokinetic profiles. Among various lipid-based systems, self-emulsifying formulations have gained considerable attention due to their simplicity and high efficiency.

Concept and Evolution of Self-Microemulsifying Drug Delivery Systems (SMEDDS)

Self-Microemulsifying Drug Delivery Systems (SMEDDS) are isotropic mixtures of oils, surfactants, and co-surfactants that possess the unique ability to form fine oil-in-water microemulsions spontaneously upon mild agitation in aqueous media, such as gastrointestinal fluids. The formation of microemulsions with droplet sizes typically below 100 nm provides a large interfacial surface area, enabling rapid drug release and absorption. Initially, SMEDDS were developed as liquid formulations filled into soft or hard gelatin capsules to improve the bioavailability of lipophilic drugs. Over time, advancements in excipient selection, phase behavior studies, and formulation optimization have expanded their application to a wide range of therapeutic classes. The success of SMEDDS lies in their ability to maintain drugs in a solubilized state in vivo, thereby overcoming dissolution-limited absorption and enhancing oral bioavailability.

Limitations of Liquid SMEDDS

Despite their advantages, conventional liquid SMEDDS suffer from several formulation and manufacturing limitations. These systems often exhibit poor physical stability, with risks of drug precipitation upon storage or dilution. The presence of high concentrations of surfactants may cause gastrointestinal irritation. Liquid SMEDDS are also associated with handling difficulties, such as leakage, capsule incompatibility, and interaction with gelatin shells leading to capsule brittleness or deformation. From an industrial perspective, liquid formulations pose challenges in terms of dosage uniformity, scalability, and long-term stability. Furthermore, patient acceptability may be compromised due to the liquid nature of the dosage form, which limits flexibility in developing conventional solid dosage forms such as tablets or pellets.

Rationale for Solidification of SMEDDS (S-SMEDDS)

To overcome the drawbacks associated with liquid SMEDDS, the concept of Solid Self-Microemulsifying Drug Delivery Systems (S-SMEDDS) was introduced. Solidification involves converting liquid SMEDDS into solid intermediates using techniques such as adsorption onto solid carriers, spray drying, freeze drying, melt granulation, or hot-melt extrusion. S-SMEDDS combine the bioavailability enhancement potential of SMEDDS with the advantages of solid dosage forms, including improved stability, ease of handling, better patient compliance, and compatibility with large-scale manufacturing. Importantly, upon exposure to gastrointestinal fluids, S-SMEDDS retain their ability to reconstitute rapidly into microemulsions, ensuring efficient drug release and absorption. Thus, solidification represents a rational and industrially feasible strategy to translate SMEDDS into patient-friendly and commercially viable products.

Comparative Overview of Liquid SMEDDS vs Solid SMEDDS

Parameter	Liquid SMEDDS	Solid SMEDDS (S-SMEDDS)
Physical state	Liquid	Solid (powder, granules, tablets, capsules)
Stability	Risk of leakage and precipitation	Improved physical and chemical stability
Handling	Difficult, leakage issues	Easy handling and storage
Dosage form flexibility	Limited	High (tablets, pellets, capsules)
Patient compliance	Moderate	High
Industrial feasibility	Limited	More suitable for scale-up



Self-Microemulsifying Drug Delivery Systems (SMEDDS)

Self-Microemulsifying Drug Delivery Systems (SMEDDS) represent an advanced class of lipid-based oral drug delivery systems specifically designed to enhance the solubility and bioavailability of poorly water-soluble drugs. These systems have gained wide acceptance in pharmaceutical research due to their simplicity, efficiency, and ability to overcome dissolution-limited absorption.

Definition and Principle

SMEDDS are thermodynamically stable, isotropic mixtures of oils, surfactants, and co-surfactants, which possess the inherent ability to form fine oil-in-water (o/w) microemulsions upon mild agitation in aqueous media, such as gastrointestinal (GI) fluids. Unlike conventional emulsions that require high-energy input, SMEDDS spontaneously emulsify due to the optimized balance between interfacial tension reduction and system entropy.

The fundamental principle of SMEDDS lies in the free energy of microemulsion formation, which is either very low or negative. This allows the system to disperse spontaneously when exposed to GI fluids, forming microemulsion droplets typically below 100 nm in size. The formation of such small droplets provides a large interfacial surface area, ensuring that the drug remains in a solubilized state and becomes readily available for absorption across the intestinal epithelium.

Mechanism of Spontaneous Microemulsion Formation

Upon oral administration, SMEDDS come in contact with aqueous gastrointestinal fluids. The gentle agitation provided by gastric and intestinal motility facilitates the rapid dispersion of the formulation. Surfactants and co-surfactants orient themselves at the oil–water interface, significantly reducing interfacial tension and promoting droplet formation. The entropy gained by dispersing oil droplets throughout the aqueous phase outweighs the energy required to create new interfaces, resulting in spontaneous microemulsification.

Once formed, the microemulsion droplets encapsulate the lipophilic drug within the oil core, preventing drug precipitation even upon extensive

dilution. This mechanism ensures consistent drug presentation in dissolved form, which is critical for absorption of BCS Class II and IV drugs.

Role of Gastrointestinal Motility and Dilution

Gastrointestinal motility plays a crucial role in the performance of SMEDDS. Peristaltic movements provide the mild agitation necessary for emulsification, while continuous dilution by gastric and intestinal fluids ensures uniform dispersion of droplets. Unlike conventional formulations, SMEDDS are designed to withstand extreme dilution without phase separation or drug precipitation. Furthermore, interaction with bile salts and phospholipids present in the intestine leads to the formation of mixed micelles, which further enhance drug solubilization and facilitate transport across the intestinal membrane.

Components of SMEDDS

The performance of SMEDDS largely depends on the type and proportion of excipients used. Each component plays a specific role in achieving spontaneous emulsification and maintaining drug solubilization.

Oils (Long-Chain and Medium-Chain Triglycerides)

Oils serve as the primary solvent for lipophilic drugs and significantly influence drug loading and bioavailability. Long-chain triglycerides (LCTs) enhance lymphatic transport and reduce first-pass metabolism, whereas medium-chain triglycerides (MCTs) exhibit superior emulsification efficiency and faster digestion. Selection of oil is based on drug solubility, emulsification ability, and metabolic pathway. Often, a combination of oils is used to balance emulsification efficiency and absorption enhancement.

Surfactants (HLB Value Considerations)

Surfactants are essential for reducing interfacial tension between the oil and aqueous phases. For SMEDDS, non-ionic surfactants with high Hydrophilic–Lipophilic Balance (HLB) values (≥12) are preferred due to their lower toxicity and better biocompatibility. High HLB surfactants promote the formation of stable oil-in-water microemulsions. However, excessive surfactant concentrations may lead to gastrointestinal irritation, making careful optimization crucial.

Co-Surfactants / Co-Solvents

Co-surfactants and co-solvents enhance the flexibility of the interfacial film and further reduce interfacial tension. They facilitate microemulsion formation at lower surfactant concentrations and improve drug solubilization. Short-chain alcohols, glycols, and polyethylene glycol derivatives are commonly used. Their presence expands the microemulsion region in phase diagrams, offering greater formulation flexibility.

Drug Incorporation Aspects

The drug must exhibit sufficient solubility in the lipid phase to ensure stable incorporation within SMEDDS. Drug loading is influenced by physicochemical properties such as lipophilicity, melting point, and molecular structure. High drug loading without precipitation upon dilution is a critical requirement. Preformulation studies involving solubility screening and phase behavior analysis are essential to identify optimal excipient combinations.

Typical Components Used in SMEDDS

Component	Function	Examples
Oils	Drug solubilization, absorption enhancement	MCT, LCT, vegetable oils
Surfactants	Reduce interfacial tension	Non-ionic surfactants (high HLB)
Co-surfactants	Improve emulsification	Glycols, PEG derivatives
Drug	Therapeutic agent	Lipophilic APIs

Advantages and Limitations of Liquid SMEDDS

Improved Dissolution and Absorption

One of the most significant advantages of liquid SMEDDS is their ability to dramatically improve drug dissolution and oral absorption. By maintaining the drug in a solubilized form throughout gastrointestinal transit, SMEDDS eliminate the dissolution step, which is often the rate-limiting factor for poorly soluble drugs. The small droplet size enhances diffusion and promotes intimate contact with the intestinal mucosa, leading to improved and reproducible bioavailability.

Stability, Leakage, and Capsule Incompatibility Issues

Despite their biopharmaceutical advantages, liquid SMEDDS suffer from several practical limitations. Liquid formulations are prone to leakage during encapsulation and storage, particularly when filled into hard gelatin capsules. Additionally, interactions between formulation components and gelatin shells may result in capsule softening, brittleness, or deformation. Long-term storage may also lead to drug precipitation, phase separation, or oxidative degradation. These issues limit large-scale manufacturing, dosage form flexibility, and patient acceptability.

Advantages vs Limitations of Liquid SMEDDS

Aspect	Advantages	Limitations
Drug dissolution	Rapid and complete	—
Bioavailability	Significantly enhanced	—
Stability	—	Risk of precipitation
Handling	—	Leakage and encapsulation issues
Dosage form	—	Limited to liquid-filled capsules

SMEDDS represent a powerful formulation strategy for enhancing the oral delivery of poorly soluble drugs. While liquid SMEDDS offer remarkable improvements in dissolution and absorption, their formulation and manufacturing challenges have driven the development of solid SMEDDS, which aim to retain biopharmaceutical benefits while improving stability and patient compliance.

Solid Self-Microemulsifying Drug Delivery Systems (S-SMEDDS)

Concept and Need for Solidification

Solid Self-Microemulsifying Drug Delivery Systems (S-SMEDDS) are advanced formulations obtained by converting conventional liquid SMEDDS into solid, free-flowing systems while preserving their inherent self-microemulsifying properties. The fundamental concept of S-SMEDDS is to combine the biopharmaceutical advantages of lipid-based self-emulsifying systems with the technological and patient-friendly benefits of solid dosage forms. In these systems, the liquid SMEDDS formulation is incorporated into suitable solid carriers or transformed into solid intermediates using various solidification techniques, ensuring that the formulation rapidly reconstitutes into a fine microemulsion upon contact with gastrointestinal fluids.

The need for solidification arises primarily from the limitations associated with liquid SMEDDS in terms of stability, handling, and large-scale manufacturing feasibility. Liquid formulations are prone to leakage, phase separation, and incompatibility with capsule shells, which may compromise product quality and shelf life. Solidification improves physical and chemical stability, minimizes drug precipitation during storage, and enables incorporation into conventional solid dosage forms such as tablets, capsules, and pellets. Moreover, solid SMEDDS offer enhanced patient compliance, as solid oral dosage forms are generally preferred due to ease of administration, portability, and accurate dosing. From an industrial perspective, S-SMEDDS facilitate scalability, reproducibility, and regulatory compliance, making them more suitable for commercial development.

Overcoming Drawbacks of Liquid Formulations

Solidification effectively addresses the major drawbacks of liquid SMEDDS. By immobilizing the liquid formulation within or onto solid excipients, issues related to leakage, capsule deformation, and excipient–shell interactions are eliminated. Additionally, solid systems exhibit better content uniformity and dose precision, which are critical quality attributes for oral dosage forms. Solid SMEDDS also reduce the risk of oxidative degradation and hydrolytic instability, thereby extending product shelf life. Importantly, despite being in a solid state, these systems retain their ability to rapidly self-emulsify in vivo, ensuring that the drug is presented in a solubilized form for efficient absorption.

Advantages of S-SMEDDS over Liquid SMEDDS

Solid SMEDDS offer several advantages over their liquid counterparts, making them an attractive option for both formulation scientists and pharmaceutical manufacturers. One of the most significant benefits is enhanced stability, as solid systems are less susceptible to phase separation, drug precipitation, and chemical degradation during storage. The transformation into a solid form also improves ease of handling, allowing the formulation to be processed using standard pharmaceutical equipment for blending, compression, or encapsulation.

Another notable advantage is the possibility of achieving modified or controlled drug release. By selecting appropriate solid carriers and polymers, S-SMEDDS can be designed to provide immediate, sustained, or site-specific drug release. This level of flexibility is difficult to achieve with liquid SMEDDS. Furthermore, solid systems offer better patient acceptability, portability, and dosing convenience, which collectively enhance therapeutic adherence.

Comparison between Liquid SMEDDS and S-SMEDDS

Parameter	Liquid SMEDDS	Solid SMEDDS (S-SMEDDS)
Physical state	Liquid	Solid (powder, granules, tablets)
Stability	Moderate; risk of leakage and precipitation	High; improved physical and chemical stability
Handling	Difficult	Easy and convenient
Dosage form flexibility	Limited	High
Controlled release potential	Limited	Possible
Patient compliance	Moderate	High

Excipients Used in S-SMEDDS

The successful development of S-SMEDDS relies heavily on the selection of appropriate excipients that can efficiently convert liquid SMEDDS into solid systems without compromising their self-emulsifying behavior. These excipients primarily include solid carriers/adsorbents and polymers/binders, each serving distinct functional roles.

Solid Carriers / Adsorbents

Solid carriers or adsorbents are key components used to absorb or adsorb liquid SMEDDS, resulting in free-flowing powders with good compressibility. Porous carriers, such as silicates and polymer-based materials, are widely employed due to their high surface area and adsorption capacity. These materials entrap the liquid formulation within their porous structure, preventing leakage while maintaining rapid reconstitution upon contact with aqueous media.

Adsorption capacity is a critical parameter, as it determines the maximum amount of liquid SMEDDS that can be incorporated without compromising powder flow or compressibility. An ideal carrier should possess high liquid-holding capacity, good flow properties, low density, and chemical inertness. Additionally, the carrier should not interfere with microemulsion formation after administration. Proper selection and optimization of solid carriers ensure uniform drug distribution, ease of processing, and consistent in-vivo performance.

Role of Flow Properties

Good flow properties are essential for the large-scale manufacturing of S-SMEDDS, particularly when formulated as tablets or capsules. Poor flow can lead to weight variation and content non-uniformity. Porous carriers with appropriate particle size and morphology contribute to improved flowability, ensuring smooth processing during blending, filling, and compression operations.

Polymers and Binders

Polymers and binders play a crucial role in imparting mechanical strength, stability, and drug release control to S-SMEDDS formulations. These polymers can be broadly classified as hydrophilic or hydrophobic, each influencing the release behavior of the incorporated drug.

Hydrophilic polymers promote rapid water uptake and swelling, facilitating quick microemulsion formation and immediate drug release. In contrast, hydrophobic polymers restrict water penetration, enabling sustained or controlled drug release. The choice of polymer is therefore guided by the desired release profile, drug properties, and therapeutic requirements.

Role in Drug Release Modulation

Polymers in S-SMEDDS serve as functional excipients that modulate drug release by controlling matrix hydration, erosion, or diffusion. By optimizing polymer type and concentration, formulators can tailor the release kinetics without affecting the self-emulsification efficiency. This makes S-SMEDDS a versatile platform for designing formulations with customized release characteristics, ranging from immediate to extended release.

Key Excipients Used in S-SMEDDS

Excipient Type	Function	Key Contribution
Solid carriers / adsorbents	Solidification of liquid SMEDDS	Improved stability and flow
Porous materials	High adsorption capacity	Prevention of leakage
Hydrophilic polymers	Rapid hydration	Immediate drug release
Hydrophobic polymers	Limited water penetration	Controlled drug release

S-SMEDDS represent a significant advancement over liquid self-emulsifying systems by addressing formulation, manufacturing, and patient-related challenges. The judicious selection of solid carriers and polymers enables the development of stable, robust, and flexible dosage forms while preserving the bioavailability-enhancing benefits of SMEDDS. These attributes make S-SMEDDS a promising and industrially viable strategy for the oral delivery of poorly water-soluble drugs.

METHODS OF PREPARATION OF SOLID SELF-MICROEMULSIFYING DRUG DELIVERY SYSTEMS (S-SMEDDS)

The preparation of Solid Self-Microemulsifying Drug Delivery Systems (S-SMEDDS) involves converting optimized liquid SMEDDS into solid, stable, and free-flowing systems without compromising their self-emulsification efficiency. Selection of the preparation method depends on factors such as drug properties, type of excipients, desired dosage form, scalability, and release characteristics. Various solidification techniques have been developed, each offering specific advantages and limitations.

Adsorption onto Solid Carriers

Adsorption onto solid carriers is one of the most widely used and simplest techniques for preparing S-SMEDDS. In this method, the liquid SMEDDS formulation is gradually added to a porous solid carrier with continuous mixing until a dry, free-flowing powder is obtained. The liquid formulation becomes entrapped within the pores or adsorbed onto the surface of the carrier, resulting in solidification.

This technique is favored due to its simplicity, cost-effectiveness, and suitability for large-scale production. The resultant powders exhibit good flow properties and can be directly filled into capsules or compressed into tablets. However, the success of this method largely depends on the adsorption capacity and porosity of the carrier, as excessive liquid loading may lead to poor flow or agglomeration. Importantly, upon contact with aqueous media, the solidified system rapidly releases the liquid SMEDDS and forms a microemulsion, preserving its in-vivo performance.

Spray Drying Technique

Spray drying is a commonly employed technique for converting liquid SMEDDS into fine, dry powders with controlled particle size. In this process, the liquid SMEDDS is dispersed or dissolved in a suitable volatile solvent along with a solid carrier or polymer to form a feed solution or suspension. This feed is then atomized into a stream of hot air, causing rapid solvent evaporation and formation of solid microparticles.

Spray drying offers advantages such as uniform particle size distribution, improved content uniformity, and enhanced dissolution performance. It is particularly useful for producing S-SMEDDS with improved compressibility and flow. However, exposure to elevated temperatures may pose a risk for thermolabile drugs, and careful optimization of process parameters is required to prevent degradation or loss of self-emulsifying properties.

Freeze Drying (Lyophilization)

Freeze drying, or lyophilization, is employed when the formulation contains temperature-sensitive drugs or excipients. In this technique, the liquid SMEDDS is first frozen and then subjected to sublimation under reduced pressure, removing water or solvent without applying heat. The result is a porous, lightweight solid matrix.

Freeze-dried S-SMEDDS exhibit excellent reconstitution properties, enabling rapid microemulsion formation upon hydration. Despite these advantages, lyophilization is time-consuming, expensive, and less suitable for large-scale industrial production, limiting its widespread application. Additionally, the fragile nature of freeze-dried products may require further processing to improve mechanical strength.

Melt Granulation Technique

Melt granulation involves the use of thermoplastic binders or carriers that melt upon heating and act as granulating agents. In this method, liquid SMEDDS is incorporated into the molten carrier, and upon cooling, solid granules are formed. These granules can be directly compressed into tablets or filled into capsules.

This technique eliminates the need for solvents, making it an environmentally friendly and efficient approach. Melt granulation improves flowability, compressibility, and content uniformity of the final product. However, the method is not suitable for drugs that are sensitive to heat, and careful temperature control is essential to avoid degradation.

Hot-Melt Extrusion (HME)

Hot-melt extrusion is an advanced and continuous manufacturing technique used to prepare S-SMEDDS by mixing liquid SMEDDS with suitable polymers under controlled heat and shear. The mixture is extruded through a die to form solid extrudates, which are then milled into granules or shaped into final dosage forms.

HME offers several advantages, including excellent content uniformity, solvent-free processing, scalability, and process reproducibility. It also allows incorporation of polymers that can modulate drug release, enabling the development of

immediate or sustained-release S-SMEDDS. However, high processing temperatures and shear stress may limit its use for thermolabile compounds.

Capsule Filling and Tablet Compression

Once solid intermediates of S-SMEDDS are obtained through any of the above techniques, they can be formulated into conventional solid dosage forms. Capsule filling is suitable for free-flowing powders or granules, while tablet compression requires materials with adequate compressibility and mechanical strength.

These conventional processes enhance patient compliance, dose accuracy, and product stability. Importantly, the formulation must retain its ability to self-emulsify upon exposure to gastrointestinal fluids after compression or encapsulation.

Comparative Summary of Preparation Methods for S-SMEDDS

Method	Key Advantages	Limitations
Adsorption onto carriers	Simple, cost-effective, scalable	Limited liquid loading
Spray drying	Uniform particles, good flow	Thermal stress
Freeze drying	Suitable for thermolabile drugs	High cost, low scalability
Melt granulation	Solvent-free, good compressibility	Heat sensitivity
Hot-melt extrusion	Continuous, reproducible	High temperature exposure
Capsule filling / compression	Patient-friendly dosage forms	Requires good flow/compressibility

The choice of preparation method plays a decisive role in determining the physicochemical properties, stability, and in-vivo performance of S-SMEDDS. Each technique offers distinct advantages and must be selected based on drug characteristics, formulation objectives, and industrial feasibility. Proper optimization ensures that the solidified system retains the self-microemulsifying behavior of liquid SMEDDS while offering the benefits of solid dosage forms.

CHARACTERIZATION AND EVALUATION OF SOLID SELF-MICROEMULSIFYING DRUG DELIVERY SYSTEMS (S-SMEDDS)

Comprehensive characterization and evaluation of S-SMEDDS are essential to ensure that solidification does not compromise the self-microemulsifying properties of the system and that the formulation consistently delivers the drug in a solubilized and bioavailable form. Evaluation parameters generally include pre-formulation studies, physicochemical characterization, solid-state analysis, in-vitro performance testing, and in-vivo assessment, each providing critical insight into formulation quality, stability, and therapeutic performance.

Pre-formulation Studies

Pre-formulation studies form the foundation for successful development of S-SMEDDS. These studies primarily involve solubility screening of the drug in various oils, surfactants, and co-surfactants to identify suitable components capable of dissolving the drug at therapeutically relevant concentrations. High drug solubility in the lipid phase is essential to prevent precipitation upon dilution in gastrointestinal fluids.

Phase behavior studies are conducted to determine the self-microemulsifying region using **pseudo-ternary phase diagrams**, which help in selecting optimal ratios of oil, surfactant, and co-surfactant. These diagrams provide valuable information on formulation robustness and the extent of microemulsion formation upon dilution. Additionally, drug–excipient compatibility studies are performed to ensure chemical and physical stability of the formulation prior to solidification.

Physicochemical Evaluation

Physicochemical evaluation is performed to assess whether S-SMEDDS retain the essential characteristics of liquid SMEDDS after solidification.

- **Droplet size and polydispersity index (PDI)** are measured after reconstitution of S-SMEDDS in aqueous media. Small droplet size with narrow size distribution indicates efficient self-emulsification and predicts improved dissolution and absorption.

  Zeta potential provides information on the surface charge of microemulsion droplets and is an indicator of dispersion stability.
- **Self-emulsification time** is evaluated to determine the rapidity with which the solid system disperses and forms a microemulsion upon contact with aqueous media.

  Drug content and content uniformity ensure accurate dosing and homogeneous drug distribution within the solid formulation.
- **Flow properties**, including angle of repose, bulk density, tapped density, Carr's index, and Hausner's ratio, are assessed to confirm suitability for capsule filling or tablet compression.

Solid-State Characterization

Solid-state characterization is crucial for understanding the physical nature of the drug within S-SMEDDS and for detecting any changes induced during solidification.

- **Fourier Transform Infrared Spectroscopy (FTIR)** is used to evaluate potential drug–excipient interactions by identifying shifts or disappearance of characteristic peaks.
  Differential Scanning Calorimetry (DSC) provides information on thermal behavior and helps determine whether the drug remains crystalline or is converted to an amorphous or molecularly dispersed state.
- **Powder X-ray Diffraction (XRD)** complements DSC by confirming changes in crystallinity.
  Scanning Electron Microscopy (SEM) is employed to study surface morphology, particle shape, and distribution of liquid SMEDDS within the solid carrier.

In-Vitro Evaluation

In-vitro evaluation is conducted to predict in-vivo performance and ensure consistent drug release behavior.

- **In-vitro dissolution studies** compare the release profile of S-SMEDDS with conventional dosage forms or liquid SMEDDS, demonstrating the enhancement in dissolution rate and extent.
- **Diffusion or permeation studies**, using suitable membranes, assess the ability of the formulation to facilitate drug transport across biological barriers.
  Supersaturation and precipitation studies evaluate the ability of S-SMEDDS to maintain the drug in a solubilized state for prolonged periods after dilution, which is critical for sustained absorption.

In-Vivo Evaluation

In-vivo studies are essential to confirm the biopharmaceutical advantages of S-SMEDDS observed during in-vitro testing.

- **Pharmacokinetic studies** assess parameters such as peak plasma concentration, time to reach peak concentration, and area under the curve to determine improvements in oral bioavailability.
- **Bioavailability studies** compare S-SMEDDS with conventional formulations to establish the extent of enhancement achieved.

Where applicable, in-vitro–in-vivo correlation (IVIVC) is explored to relate dissolution behavior with systemic drug exposure, supporting formulation optimization and regulatory approval.

Summary of Characterization and Evaluation Parameters

Evaluation Category	Key Parameters	Purpose
Pre-formulation	Solubility, phase behavior, compatibility	Component selection
Physicochemical	Droplet size, PDI, zeta potential, flow	Performance and processability
Solid-state	FTIR, DSC, XRD, SEM	Drug state and stability
In-vitro	Dissolution, diffusion, supersaturation	Predict in-vivo behavior
In-vivo	Pharmacokinetics, bioavailability	Therapeutic effectiveness

Systematic characterization and evaluation of S-SMEDDS ensure that the advantages of self-microemulsifying systems are preserved after solidification. By integrating physicochemical, solid-state, and biopharmaceutical assessments, researchers can develop robust and reproducible S-SMEDDS with enhanced stability, predictable performance, and superior oral bioavailability. This comprehensive evaluation framework is essential for successful translation of S-SMEDDS from laboratory research to clinical and industrial applications.

APPLICATIONS OF SOLID SELF-MICROEMULSIFYING DRUG DELIVERY SYSTEMS (S-SMEDDS)

Solid Self-Microemulsifying Drug Delivery Systems (S-SMEDDS) have found wide-ranging applications across multiple therapeutic categories due to their proven ability to enhance the oral bioavailability of poorly water-soluble drugs. By maintaining drugs in a solubilized state after oral administration and offering the advantages of solid dosage forms, S-SMEDDS provide an effective platform for improving therapeutic efficacy, dose uniformity, and patient compliance.

Antidiabetic Drugs

Many antidiabetic agents, particularly those belonging to newer chemical classes, exhibit poor aqueous solubility and variable oral bioavailability. This often leads to inconsistent glycemic control and the need for higher doses. S-SMEDDS improve the oral performance of antidiabetic drugs by enhancing dissolution rate and intestinal absorption. The lipid-based nature of these systems facilitates rapid microemulsion formation in gastrointestinal fluids, ensuring consistent drug

availability at the absorption site. Additionally, S-SMEDDS can reduce food-dependent variability and improve pharmacokinetic reproducibility, which is crucial for maintaining stable blood glucose levels. The possibility of developing sustained-release S-SMEDDS further supports better glycemic management and reduced dosing frequency.

Anticancer Agents

Oral delivery of anticancer drugs is often limited by low solubility, poor permeability, and extensive first-pass metabolism. S-SMEDDS offer a promising approach to overcome these challenges by enhancing solubilization and promoting lymphatic uptake, which may reduce hepatic metabolism. Improved bioavailability achieved through S-SMEDDS can lead to lower required doses and reduced systemic toxicity. Moreover, solid formulations allow for accurate dosing and improved patient adherence, which is particularly important in long-term cancer therapy. The ability to incorporate polymers into S-SMEDDS also enables controlled or targeted drug release, further improving therapeutic outcomes.

Antifungal and Antiviral Drugs

Several antifungal and antiviral drugs are highly lipophilic and exhibit erratic absorption following oral administration. S-SMEDDS enhance the dissolution and absorption of these agents by forming stable microemulsions upon contact with gastrointestinal fluids. Improved solubilization leads to higher and more consistent plasma drug concentrations, which is essential for effective management of systemic fungal and viral infections. Solidification of SMEDDS into S-SMEDDS improves formulation stability and shelf life, making these systems suitable for chronic and prophylactic therapies where long-term storage and patient convenience are critical.

Central Nervous System (CNS) Drugs

CNS-active drugs often suffer from low oral bioavailability due to poor solubility and extensive first-pass metabolism. S-SMEDDS enhance the oral delivery of such drugs by increasing dissolution rate and facilitating rapid absorption. The lipid components of S-SMEDDS may also aid in improving drug transport across biological membranes, contributing to enhanced systemic exposure. Solid dosage forms provide precise dosing and improved patient compliance, which is particularly important for CNS disorders requiring long-term treatment. Additionally, the potential to design modified-release S-SMEDDS supports sustained therapeutic levels, minimizing fluctuations in plasma concentration.

Herbal Phytoconstituents

Herbal phytoconstituents, such as polyphenols, flavonoids, terpenoids, and alkaloids, often exhibit poor water solubility and limited oral bioavailability, restricting their clinical effectiveness despite potent pharmacological activity. S-SMEDDS have emerged as an effective strategy to enhance the bioavailability of these natural compounds by improving solubilization and protecting them from degradation in the gastrointestinal environment. Solidification further enhances stability and enables formulation into conventional dosage forms, making herbal products more acceptable for clinical use. By improving absorption and consistency of therapeutic response, S-SMEDDS help bridge the gap between traditional herbal medicine and modern pharmaceutical delivery systems.

Summary of Applications of S-SMEDDS

Therapeutic Category	Key Challenges	Benefits of S-SMEDDS
Antidiabetic drugs	Poor solubility, variable absorption	Improved bioavailability, consistent glycemic control
Anticancer agents	Low solubility, first-pass metabolism	Enhanced absorption, reduced dose variability
Antifungal & antiviral drugs	Erratic absorption	Improved plasma levels and stability
CNS drugs	Poor solubility, metabolism	Better systemic exposure and patient compliance
Herbal phytoconstituents	Low solubility, instability	Enhanced absorption and formulation stability

The versatility of S-SMEDDS makes them applicable to a broad spectrum of therapeutic agents, ranging from synthetic drugs to natural phytoconstituents. By addressing solubility- and absorption-related challenges while offering the advantages of solid dosage forms, S-SMEDDS represent a robust and adaptable drug delivery platform with significant potential for improving clinical outcomes across diverse disease areas.

CONCLUSION:

Solid Self-Microemulsifying Drug Delivery Systems have emerged as a robust and versatile formulation strategy for addressing the persistent challenge of poor oral bioavailability associated with poorly water-soluble drugs. By transforming liquid SMEDDS into solid dosage forms, S-SMEDDS successfully overcome key limitations such as leakage, instability, handling difficulties, and limited manufacturability, while retaining the ability to rapidly form microemulsions in gastrointestinal conditions. The judicious selection of oils, surfactants, solid carriers, and polymers, along with appropriate solidification techniques, plays a critical role in maintaining self-emulsification efficiency and ensuring consistent in-vivo performance. Comprehensive characterization and evaluation approaches further support the development of stable, reproducible, and patient-friendly formulations. The wide applicability of S-SMEDDS across therapeutic categories, including synthetic drugs and herbal phytoconstituents, underscores their significance in modern drug delivery research.

In conclusion, S-SMEDDS represent a scientifically sound and industrially feasible platform with strong potential for future pharmaceutical development. Continued advancements in excipient technology, process optimization, and regulatory understanding are expected to further expand their clinical and commercial success.

CONFLICT OF INTREST:

None

REFERENCES:

1. Pouton CW. Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev. 1997;25(1):47–58.
2. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and self-microemulsifying drug delivery systems. Eur J Pharm Sci. 2000;11(Suppl 2):S93–S98.
3. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231–248.
4. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004;58(3):173–182.
5. Tang B, Cheng G, Gu JC, Xu CH. Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage forms. Drug Discov Today. 2008;13(13–14):606–612.
6. Nazzal S, Smalyukh II, Lavrentovich OD, Khan MA. Preparation and in vitro characterization of a eutectic-based semisolid self-nanoemulsified drug delivery system. Int J Pharm. 2002;235(1–2):247–265.
7. Shah NH, Carvajal MT, Patel CI, Infeld MH, Malick AW. Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm. 1994;106(1):15–23.
8. Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm. 2001;212(2):233–246.
9. Patel AR, Vavia PR. Preparation and in vivo evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate. AAPS J. 2007;9(3):E344–E352.
10. Balakrishnan P, Lee BJ, Oh DH, Kim JO, Hong MJ, Jee JP, et al. Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS). Eur J Pharm Biopharm. 2009;72(3):539–545.
11. Wang Z, Sun J, Wang Y, Liu X, Liu Y, Fu Q, et al. Solid self-emulsifying drug delivery systems of tacrolimus prepared by spray drying: physicochemical characterization and pharmacokinetic study. Int J Pharm. 2010;397(1–2):239–246.
12. Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci. 1999;88(10):1058–1066.
13. Patel J, Kevin G, Patel A, Raval M, Sheth N. Design and development of a self-microemulsifying drug delivery system for telmisartan for oral drug delivery. Int J Pharm Investig. 2011;1(2):112–118.
14. Kang MJ, Jung SY, Song WH, Park JS, Choi SU, Oh KT, et al. Immediate release of ibuprofen from FDM 3D-printed tablets prepared by a hot-melt extrusion-based filament. Pharmaceutics. 2021;13(2):292.

15. Beg S, Swain S, Singh HP, Patra CN, Rao ME. Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of valsartan using porous carriers. AAPS PharmSciTech. 2012;13(4):1416–1427.
16. Jannin V, Musakhanian J, Marchaud D. Approaches for the development of solid and semi-solid lipid-based formulations. Adv Drug Deliv Rev. 2008;60(6):734–746.
17. Rao SVR, Shao J. Self-microemulsifying drug delivery systems (SMEDDS) for oral delivery of protein drugs: I. Formulation development. Int J Pharm. 2008;362(1–2):2–9.
18. Dokania S, Joshi AK. Self-microemulsifying drug delivery system (SMEDDS) – challenges and road ahead. Drug Deliv. 2015;22(6):675–690.
19. Bansal T, Mustafa G, Khan ZI, Ahmad FJ, Khar RK. Solid self-nanoemulsifying drug delivery systems as a platform technology for formulation of poorly soluble drugs. Crit Rev Ther Drug Carrier Syst. 2008;25(1):63–116.
20. Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm. 2002;231(2):131–144.
21. Rane SS, Anderson BD. What determines drug solubility in lipid vehicles: is it predictable? Adv Drug Deliv Rev. 2008;60(6):638–656.
22. Kuentz M. Lipid-based formulations for oral delivery of lipophilic drugs. Drug Discov Today Technol. 2012;9(2):e97–e104.
23. Dressman JB, Reppas C. In vitro–in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci. 2000;11(Suppl 2):S73–S80.
24. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm. 2007;66(2):227–243.
25. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption. J Pharm Sci. 1995;84(6):713–720.
26. Grove M, Müllertz A, Pedersen GP, Nielsen JL. Bioavailability of seocalcitol II: development and characterisation of self-microemulsifying drug delivery systems (SMEDDS). Eur J Pharm Sci. 2006;28(3):233–242.
27. Rasve V, Chakraborty AK, Jain SK, Vengurlekar S. Study of phytochemical profiling and in vitro studies on antioxidant properties of ethanolic extract of *Clematis triloba*. Eur Chem Bull. 2022;11(12):2658–2677. doi:10.53555/ecb/2022.11.12.2162022.
28. Date AA, Desai N, Dixit R, Nagarsenker M. Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomedicine. 2010;5(10):1595–1616.
29. Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B. 2015;5(5):442–453.
30. Shahba AA, Mohsin K, Alanazi FK. Novel self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of vitamin D3. Drug Dev Ind Pharm. 2012;38(9):1021–1029.
31. McClements DJ. Nanoemulsions versus microemulsions: terminology, differences, and similarities. Soft Matter. 2012;8:1719–1729.
32. Dixit RP, Nagarsenker MS. Self-nanoemulsifying granules of ezetimibe: design, optimization, and evaluation. Eur J Pharm Sci. 2008;35(3):183–192.
33. Kim CK, Cho YJ, Gao ZG. Preparation and evaluation of biphasic release microspheres of acebutolol hydrochloride. J Control Release. 2001;75(1–2):159–168.
34. United States Pharmacopeia. USP–NF. Rockville (MD): United States Pharmacopeial Convention; latest ed.
35. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. 6th ed. London: Pharmaceutical Press; 2009.
36. Aulton ME, Taylor KMG. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 4th ed. Edinburgh: Churchill Livingstone Elsevier; 2013.
37. Neslihan Gursoy R, Benita S. Lipid-based drug delivery systems for oral administration: a review. J Drug Target. 2004;12(6):369–378.
38. Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems – an overview. Acta Pharm Sin B. 2013;3(6):361–372.
39. Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release. 2008;129(1):1–10.
40. Thomas N, Holm R, Mullertz A, Rades T. In vitro and in vivo performance of lipid-based drug delivery systems: current status and future perspectives. Drug Deliv Transl Res. 2012;2:168–187.
41. Li P, Zhao L. Developing early formulations: practice and perspective. Int J Pharm. 2007;341(1–2):1–19.
42. Patel J, Patel A, Raval M, Sheth N. Design and development of a self-microemulsifying drug delivery system of irbesartan. J Adv Pharm Technol Res. 2011;2(1):9–16.
43. Khan AW, Kotta S, Ansari SH, Sharma RK, Ali J. Self-nanoemulsifying drug delivery system (SNEDDS) of rosuvastatin: design, formulation, bioavailability and

pharmacodynamic evaluation. Drug Deliv. 2015;22(2):247–254.
44. Singh B, Bandopadhyay S, Kapil R, Singh R, Katare O. Self-emulsifying drug delivery systems (SEDDS): formulation development, characterization, and applications. Crit Rev Ther Drug Carrier Syst. 2009;26(5):427–521.
45. Craig DQM, Barker SA, Banning D, Booth SW. An investigation into the mechanisms of dissolution of fenofibrate from solid dispersions. J Pharm Sci. 1999;88(6):601–606.
46. Shah VP, Noory A, Noory C, McCullough B, Clarke S, Everett R, et al. In vitro dissolution of sparingly water-soluble drug dosage forms. Int J Pharm. 1995;125(1):99–106.
47. Tang JL, Sun J, He ZG. Self-emulsifying drug delivery systems: strategy for improving oral delivery of poorly soluble drugs. Curr Drug Ther. 2007;2(1):85–93.
48. Beg S, Rahman M, Jain A, Saini S, Midoux P, Pichon C, et al. Nanoprecipitation of anticancer drug loaded lipid polymer hybrid nanoparticles for targeted drug delivery. Colloids Surf B Biointerfaces. 2013;112:424–432.
49. Gao P, Rush BD, Pfund WP, Huang T, Bauer JM, Morozowich W, et al. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci. 2003;92(12):2386–2398.
50. Porter CJH, Charman WN. Uptake of drugs into the intestinal lymphatics after oral administration. Adv Drug Deliv Rev. 2001;50(1–2):61–80.
51. Rehman FU, Shah KU, Shah SU, Khan IU, Khan GM. Oral delivery of curcumin using solid lipid nanoparticles. Int J Pharm. 2013;445(1–2):157–165.
52. Nekkanti V, Venkateshwarulu V. Lipid-based drug delivery system: new paradigm for oral delivery of poorly soluble drugs. J Pharm Sci Res. 2010;2(12):790–803.
53. Gershanik T, Benita S. Positively charged self-emulsifying oil formulation for improving oral bioavailability of progesterone. Pharm Res. 1996;13(6):863–868.
54. Serajuddin ATM, Sheen PC, Augustine MA, Jarowski CI. Improved dissolution of poorly water-soluble drugs from solid dispersions in polyethylene glycol: polysorbate 80 mixtures. J Pharm Sci. 1988;77(5):414–417.
55. Holm R. Future opportunities and challenges in lipid-based formulations. Adv Drug Deliv Rev. 2019;142:118–134.
56. Khadka P, Ro J, Kim H, Kim I, Kim JT, Kim H, et al. Pharmaceutical particle technologies: an approach to improve drug solubility, dissolution and bioavailability. Asian J Pharm Sci. 2014;9(6):304–316.
57. Dokania S, Joshi AK. Lipid-based formulation design for oral drug delivery. Pharmaceutics. 2020;12(8):778.
58. Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ. Advances in oral drug delivery. Front Pharmacol. 2021;12:618411.
59. Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res. 2004;21(2):201–230.
60. Shah S, Maddineni S, Lu J, Repka MA. Melt extrusion with poorly soluble drugs. Int J Pharm. 2013;453(1):233–252.
61. Repka MA, Shah S, Lu J, Maddineni S, Morott J, Patwardhan K, et al. Melt extrusion: process to product. Expert Opin Drug Deliv. 2012;9(1):105–125.
62. Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ, Pouton CW. Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm Res. 1992;9(1):87–93.
63. Hauss DJ. Oral lipid-based formulations. Adv Drug Deliv Rev. 2007;59(7):667–676.
64. Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013;65(1):315–499.
65. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. J Pharm Pharmacol. 2010;62(11):1607–1621.
66. Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012;2012:195727.
67. Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv. 2007;4(4):403–416.
68. Müller RH, Shegokar R, Keck CM. 20 years of lipid nanoparticles (SLN & NLC): present state of development & industrial applications. Curr Drug Discov Technol. 2011;8(3):207–227.
69. Kallakunta VR, Bandari S, Jukanti R, Veerareddy PR. Oral self-emulsifying drug delivery systems (SEDDS) of lercanidipine hydrochloride: formulation and in vivo evaluation. Colloids Surf B Biointerfaces. 2012;90:173–179.
70. Patil P, Joshi P, Paradkar A. Effect of formulation variables on preparation and evaluation of gelled self-emulsifying drug delivery system (G-SEDDS). AAPS PharmSciTech. 2004;5(3):e42.
71. Jaiswal P, Aggarwal G, Harikumar SL, Singh K. Development of self-microemulsifying drug delivery system and solid self-microemulsifying drug delivery system of telmisartan. Int J Pharm Investig. 2014;4(4):195–206.

72. Shanmugam S, Baskaran R, Balakrishnan P, Thapa P, Yong CS, Yoo BK. Solid self-nanoemulsifying drug delivery system for enhanced bioavailability of bicalutamide. Pharm Dev Technol. 2011;16(5):427–435.
73. Zhang P, Liu Y, Feng N, Xu J. Preparation and evaluation of self-microemulsifying drug delivery system of oridonin. Int J Pharm. 2008;355(1–2):269–276.
74. Balakrishnan P, Lee BJ, Oh DH, Kim JO, Hong MJ, Jee JP, et al. Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system. Eur J Pharm Biopharm. 2009;72(3):539–545.
75. Mahmoud EA, Bendas ER, Mohamed MI. Preparation and evaluation of self-nanoemulsifying tablets of carvedilol. AAPS PharmSciTech. 2009;10(1):183–192.
76. Sharma S, Kaur A, Jain UK, Chandra R, Madan J. Stealth lipid polymer hybrid nanoparticles for enhanced delivery of docetaxel. Int J Pharm. 2016;507(1–2):87–96.
77. Singh AK, Chaurasiya A, Awasthi A, Mishra G, Asati D, Khar RK, et al. Oral bioavailability enhancement of exemestane from self-microemulsifying drug delivery system (SMEDDS). AAPS PharmSciTech. 2009;10(3):906–916.
78. Rasve V, Chakraborty AK, Jain SK, Vengurlekar S. Comparative evaluation of antidiabetic activity of ethanolic leaves extract of *Clematis triloba* and their SMEDDS formulation in streptozotocin-induced diabetic rats. J Popul Ther Clin Pharmacol. 2022;29(4):959–971. doi:10.53555/jptcp.v29i04.2360.
79. Kazi M, Shahba AA, Alrashoud S, Alwadei M, Sherif AY, Alanazi FK. Development and optimization of self-nanoemulsifying drug delivery systems (SNEDDS) for poorly water-soluble drugs. Pharm Dev Technol. 2019;24(4):495–503.
80. Dressman JB, Krämer J. Pharmaceutical Dissolution Testing. Boca Raton: CRC Press; 2005.
81. Banker GS, Rhodes CT. Modern Pharmaceutics. 4th ed. New York: Marcel Dekker; 2002.
82. Sinko PJ. Martin's Physical Pharmacy and Pharmaceutical Sciences. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.
83. Charman WN, Porter CJH, Mithani S, Dressman JB. Physiochemical and physiological mechanisms for the effects of food on drug absorption. Adv Drug Deliv Rev. 1997;25(1):3–28.
84. Holm R, Müllertz A. Mucoadhesive properties of lipid-based formulations. J Control Release. 2012;161(2):702–709.
85. Kim MS, Kim JS, Park HJ, Woo JS, Lee BJ. In vitro and in vivo evaluation of solid self-emulsifying drug delivery system for atorvastatin calcium. Eur J Pharm Sci. 2008;33(2):181–189.
86. Nekkanti V, Karatgi P, Prabhu R, Pillai R. Solid self-microemulsifying formulation for candesartan cilexetil. AAPS PharmSciTech. 2010;11(1):9–17.
87. Zanchetta B, Chaud MV, Santana MHA. Self-emulsifying drug delivery systems (SEDDS) in pharmaceutical development. Braz J Pharm Sci. 2015;51(2):249–266.
88. Lippacher A, Müller RH, Mäder K. Preparation of semisolid drug carrier systems based on solid lipid nanoparticles. Int J Pharm. 2001;214(1–2):9–12.
89. Nazzal S, Khan MA. Controlled release of a self-emulsifying formulation from a tablet dosage form. Pharm Technol. 2002;26(6):28–35.
90. Kotta S, Khan AW, Pramod K, Ansari SH, Sharma RK, Ali J. Exploring oral nanoemulsions for bioavailability enhancement of poorly water-soluble drugs. Expert Opin Drug Deliv. 2012;9(5):585–598.
91. Jaiswal M, Dudhe R, Sharma PK. Nanoemulsion: an advanced mode of drug delivery system. 3 Biotech. 2015;5(2):123–127.
92. Shakeel F, Ramadan W, Shafiq S. Solubility and dissolution improvement of aceclofenac using different nanocarriers. J Bioequiv Availab. 2009;1(2):39–43.